score:298
Chances:
- Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Guardant Health Stock Sees Renewed Technical Strength
- Guardant Health (GH) Reports Solid Q2 Results
- Guardant Health Receives Regulatory Approval from Singapore’s Health Sciences Authority for Guardant360® CDx blood test
- Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
Risks:
- Further weakness as Guardant Health (NASDAQ:GH) drops 3.9% this week, taking three-year losses to 56%
- Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Score:298
investment score = chances characters count - risks characters count
References:
- 2023-09-02 Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
- 2023-09-01 Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- 2023-08-23 Wall Street Analysts Believe Guardant Health (GH) Could Rally 42.09%: Here’s is How to Trade
- 2023-08-18 Guardant Health to Host Investor Day on September 7, 2023
- 2023-08-10 2 Cathie Wood Stocks to Buy and Hold for 10 Years
- 2023-08-08 Guardant Health Stock Sees Renewed Technical Strength
- 2023-08-05 Guardant Health, Inc. (NASDAQ:GH) Q2 2023 Earnings Call Transcript
- 2023-08-04 Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
- 2023-08-04 Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
- 2023-08-02 Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research